The [1,2,4]Triazolo[4,3‐a]pyridine as a New Player in the Field of IDO1 Catalytic Holo‐Inhibitors

Inhibitors of indoleamine 2,3‐dioxygenase 1 (IDO1) are considered a promising strategy in cancer immunotherapy as they are able to boost the immune response and to work in synergy with other immunotherapeutic agents. Despite the fact that no IDO1 inhibitor has been approved so far, recent studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallarini, Silvia, Bhela, Irene P., Aprile, Silvio, Torre, Enza, Ranza, Alice, Orecchini, Elena, Panfili, Eleonora, Pallotta, Maria T., Massarotti, Alberto, Serafini, Marta, Pirali, Tracey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291769/
https://www.ncbi.nlm.nih.gov/pubmed/34355531
http://dx.doi.org/10.1002/cmdc.202100446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291769/
https://www.ncbi.nlm.nih.gov/pubmed/34355531
http://dx.doi.org/10.1002/cmdc.202100446

Ejemplares similares